480 research outputs found

    Introduction

    Get PDF

    Two years of COVID-19 in the MS community: What have we learnt so far?

    Get PDF

    Chitinases and chitinase-like proteins as biomarkers in neurologic disorders

    Get PDF
    Esclerosi múltiple; Malaltia d'Alzheimer; Esclerosi lateral amiotròficaEsclerosis múltiple; Enfermedad de alzheimer; Esclerosis lateral amiotróficaMultiple sclerosis; Alzheimer's disease; Amyotrophic lateral sclerosisChitinases are hydrolytic enzymes widely distributed in nature. Despite their physiologic and pathophysiologic roles are not well understood, chitinases are emerging as biomarkers in a broad range of neurologic disorders, where in many cases, protein levels measured in the CSF have been shown to correlate with disease activity and progression. In this review, we will summarize the structural features of human chitinases and chitinase-like proteins and their potential physiologic and pathologic functions in the CNS. We will also review existing evidence for the role of chitinases and chitinase-like proteins as diagnostic and prognostic biomarkers in inflammatory, neurodegenerative diseases, and psychiatric disorders. Finally, we will comment on future perspectives of chitinase studies in neurologic conditions.No targeted funding reported

    Empreses i pluralisme informatiu

    Get PDF
    Empreses i pluralisme informati

    A plain language summary on assessing the long-term effectiveness of cladribine tablets in people living with relapsing multiple sclerosis: The CLASSIC-MS study

    Get PDF
    Cladribina; Multiple sclerosis; RelapsesCladribina; Esclerosi mĂşltiple; RecaigudesCladribina; Esclerosis mĂşltiple; RecaĂ­dasWhat is this summary about? Previous studies have shown that people living with multiple sclerosis (MS) treated with cladribine tablets have fewer relapses (where new symptoms occur or existing symptoms get worse for 24 hours or more) and delayed disability progression (slowing down of the disease getting worse). The CLASSIC-MS study looked at the long-term effectiveness of treatment with cladribine tablets in people living with MS who had taken part in the original CLARITY and CLARITY Extension clinical studies. What were the results? Results showed that people treated with cladribine tablets maintained their mobility (the ability to move freely) for longer and experienced other positive effects long after their treatment ended, including being less likely to need further treatment for their MS. What do the results mean? The results obtained from CLASSIC-MS show that the benefits of taking cladribine tablets carry on even when patients stop taking the treatment
    • …
    corecore